PD-L1 Expression and Its Association With p16 in Head and Neck Squamous Cell Carcinoma in Southwestern Uganda

Figures & data

Table 1 Baseline Characteristics of Sample Source Patients

Characteristic	Frequency	Proportion (%)
Age
10–19	1	0.61
20–29	2	1.21
30–39	13	7.88
40–49	28	16.97
50–59	36	21.82
60–69	40	24.24
70–79	31	18.79
80–89	13	7.88
90–99	1	0.61
Mean	58.72
Sex
Male	132	80
Female	33	20

Table 2 p16 Expression (Denoting HPV) in Relation to Source Patients’ Demographics and Tumor Site

Variables	Total Number	p16 Positive N (%)	p16 Negative N (%)
All HNSCC cases	165	27(16.36)	138(83.64)
AGE: <60	80	20(25)	60(75)
≥60	85	7(8.24)	78(91.76)
SEX: Male	132	18(13.6)	114(86.4)
Female	33	9(27.3)	24(72.7)
TUMOR SITE
Oropharynx	37	5(13.5)	32(86.5)
Larynx	40	4(10)	36(90)
Oral cavity	85	18(21.2)	67(78.8)
Hypopharynx	3	0(0)	3(100)

Figure 1 Prevalence of p16 expression in HNSCC.

Table 3 Association Between PD-L1 Expression and Clinico-Pathologic Characteristics of HNSCC

Parameter	Total Cases	PD-L1 Positive (N=53)	PD-L1 Negative (N=112)	Fischer’s Exact
All HNSCC cases	165
AGE: <60	80	32(40)	48(60)	0.045
≥ 60	85	21(24.71)	64(74.3)
SEX: Male	132	38(28.79)	94(71.21)	0.094
Female	33	15(45.45)	18(54.55)
TUMOR SITE
Oral cavity	85	33(38.82)	52(61.18)	0.265
Oropharynx	37	9(24.32)	28(75.68)
Larynx	40	10(25)	30(75)
Hypopharynx	3	1(33.33)	2(66.67)
Histologic grade
Well	97	32(32.99)	65(67.01)	0.968
Moderate	53	16(30.19)	37(69.81)
Poor	15	5(33.33)	10(66.67)
p16
Positive	27	19(70.37)	8(29.63)	<0.001*
Negative	138	34(24.64)	104(75.36)

Note: *Statistically significant.

Figure 2 Prevalence of PD-L1 expression in HNSCC.

Figure 3 Pictographs showing PD-L1 and p16 immunoreactivity.

Notes: (A) PD-L1 positive, (B) PD-L1 negative, (C) p16 positive, (D) p16 negative, x200.